| Autor: |
Kawish M; International Center for Chemical and Biological Sciences, H.E.J Research Institute of Chemistry, University of Karachi, Karachi, Pakistan., Ullah S; International Center for Chemical and Biological Sciences, H.E.J Research Institute of Chemistry, University of Karachi, Karachi, Pakistan., Roome T; Molecular Pathology Section, Department of Pathology, Dow Diagnostic Reference and Research Laboratory, Dow University of Health Sciences, Karachi, Pakistan.; Dow Institute for Advanced Biological and Animal Research, Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan., Razzak A; Molecular Pathology Section, Department of Pathology, Dow Diagnostic Reference and Research Laboratory, Dow University of Health Sciences, Karachi, Pakistan.; Dow Institute for Advanced Biological and Animal Research, Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan., Aslam S; Dow Institute for Advanced Biological and Animal Research, Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan., Raza Shah M; International Center for Chemical and Biological Sciences, H.E.J Research Institute of Chemistry, University of Karachi, Karachi, Pakistan. |
| Abstrakt: |
Thermoresponsive nanoparticles are exploited as drug-delivery vehicles that release their payload upon increment in temperature. We prepared and characterized thermoresponsive lipid-anchored folic acid engineered magnetic nanoparticles (LP-HP-FANPs) that combine receptor-based targeting and thermoresponsive sustained release of hesperidin (HP) in response to endogenous inflammation site temperature. The progressive surface engineering of NPs was validated by FTIR analysis. Our LP-HP-FANPs had a particle size of 100.5 ± 1.76 nm and a zeta potential of 14.6 ± 2.65 mV. The HP encapsulation effectiveness of LP-HP-FANPs is around 91 ± 0.78%. AFM scans indicated that our modified nanoparticles were spherical. LP-HP-FANPs exhibit increased drug release (85.8% at pH 4.0, 50.9% at pH 7.0) at 40 °C. Animal studies showed no toxicity from nanoparticles. Compared to conventional drugs and HP, LP-HP-FANPs effectively decreased paw edema, cytokine levels, and total cell recruitment in thioglycollate-induced peritonitis ( p < 0.05). LP-HP-FANPs substantially decreased cytokines compared to HP, HP-FA-NPs, and the standard medication ( p < 0.05, p < 0.01, and p < 0.001). These findings imply that the synthesized HP-loaded formulation (LP-HP-FANPs) may be a potential anti-inflammatory formulation for clinical development. |
